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Ageing disorders can be defined as the progressive and cumulative outcome of
several defective cellular mechanisms as well as metabolic pathways, consequently
resulting in degeneration. Environment plays an important role in its pathogenesis. In
contrast, developmental disorders arise from inherited mutations and usually the role
of environmental factors in development of disease is minimal. Age related macular
degeneration (AMD) is one such retinal degenerative disorder which starts with the
progression of age. Metabolism plays an important role in initiation of such diseases of
ageing. Cholesterol metabolism and their oxidized products like 7-ketocholesterol have
been shown to adversely impact retinal pigment epithelium (RPE) cells. These molecules
can initiate mitochondrial apoptotic processes and also influence the complements factors
and expression of angiogenic proteins like VEGF etc. In this review we highlight why
and how AMD is an ageing disorder and not a developmental disease substantiated by
disrupted cholesterol metabolism common to several age related diseases.
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INTRODUCTION
Age related macular degeneration (AMD) is described by irre-
versible vision loss in older age. The disease pathology emerges
with the degeneration of macula which forms the central part of
retina. The macula consists of photoreceptor (rods and cones)
important for central vision. As AMD symptoms appear, char-
acteristic features such as formation of drusen, consisting of
active and inactive complement associated inflammatory prod-
ucts, aggregate of lipoprotein, cell debris, oxysterols, oxidized
phospholipids and Alu RNA deposits begin to emerge later in
life and not during development. These aggregates deposit in
the extra-cellular space between Bruch’s membrane and retinal
pigment epithelium cells (RPE). Gradual and consistent effects
of these aggregates gradually cause degeneration of these cells
followed by global atrophy of RPE cells, commonly known as
geographic atrophy (GA). Besides, active inflammatory compo-
nents of these deposits between Bruch’s membrane and RPE,
stimulate angiogenic factors (e.g., VEGF, TGFB etc.) which act
on choriocapillary network beneath the Bruch’s membrane and
stimulate proliferation to new blood vessels (a process called neo-
vascularization). These newly formed blood vessels can outgrow
into the RPE cells and result in disruption of RPE cell integrity
and function which is well preserved in early life. Understand-
ing the complexity of mechanisms through genetics, epigenetics,
metabolic pathways and risk factors have provided insight about
the participation of cellular pathways that resemble aging, but
not early or late development. Cells that lose their capacity to
divide by a phenomenon called cell senescence undergo ageing.
Several impaired cellular processes could lead to cellular and
morphological changes in the cell over time in association with
environmental factors in complex manner ultimately resulting
in ageing. These cellular processes include: metabolic pathways
(Uchiki et al., 2012), telomere shortening, impaired mechanism
of autophagy, disrupted proteolytic and lysosomal function (Viiri
et al., 2013); decline in ability to combat oxidative stress (Cutler
et al., 2004) and enhanced mitochondrial dysfunction etc. all of
which can disrupt homeostasis of the cell. Therefore, age related
changes in the cell are the basis of several diseases which are
termed as age related diseases. Hence, the age related diseases
depend on the degree of ageing in cells. Several genetic loci have
been postulated to drive age related changes in the organism even
in pre-mature age (Friedman and Johnson, 1988; Kennedy et al.,
1995; Hernandez et al., 2010). Therefore, such impaired cellu-
lar, genetic or molecular processes coupled with environmental
changes result in age related disorders. Instead of age related disor-
ders, the developmental disorders are mostly inherited when other
cellular processes are intact. Infact the environmental factors also
play an important role in developmental disorders but not in
a manner representative of diseases of ageing. Therefore, future
effective interventions to combat diseases of aging shall require
comprehensive understanding of gene regulatory networks than
single gene replacement strategies.
INTERACTION BETWEEN ENVIRONMENT FACTORS AND GENETIC LOCI
It is evident that the disease pathology of AMD is equally
influenced by both environmental as well as genetic factors in a
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complex manner such that the effects are not manifest early in
life. Several environmental factors such as age, sex, diet, smoking
and demographic distribution have been reported to be strongly
associated with AMD pathology (Figure 1), unlike a developmen-
tal disorder.
EPIGENETIC CHANGES INTRODUCED BY ENVIRONMENTAL FACTORS
IN AMD
The epigenetic changes in the genome have been well defined in
several genetic diseases. These epigenetic alterations affect the 5
expression level of several important genes apart from exerting
protective role on host genome by either preventing activation
of restriction enzymes or other mechanisms. Several cancers
are believed to progress through similar chemical modifications
(epigenetic changes) of the genome which impact the expression
pattern of regulatory genes. The fundamental chemical changes
include methylation, phosphorylation, acetylation, etc. which are
reportedly involved in eukaryotes. Several environmental factors
like smoking, stress, dietary habits etc. have been well described
in introducing chemical changes on the genome (Lim and Song,
2012). Ageing can also influence the methylation pattern of the
genome (Bollati et al., 2009). These studies suggest that apart
from the inherited epigenetic changes, these changes can also be
introduced by several modulatory environmental factors espe-
cially smoking and deficiency of anti-oxidants in diets in a later
stage of life than at the developmental stage.
Similarly, there are several co-morbid conditions which have
been found to be associated with manifestation of AMD.
Persistent hypertension, heart disease and diabetes, acceler-
ate AMD pathogenesis. Lately, it has also been revealed that
Alzheimer’s disease appears to have concurrence with AMD
pathology suggesting the role of several common gene loci indi-
cating that their associated pathological mechanisms, underlying
cascade of downstream events, converge to cause the two diseases
of ageing. This review highlights the role of various candidate
genes that play an independent role in progression of AMD and
digresses on spectrum of gene association studies which modify
AMD pathology in a manner not characteristic of a development
disorder.
The genes associated with AMD can be conveniently cate-
gorized into following groups based on their direct or indirect
association reported in various studies:
1. Complement system components: e.g., complement factor H
(CFH), component C2, component C3 and complement fac-
tor I (CFI). Moreover, TLRs receptor components of innate
immunity have also been found to be strongly associated with
AMD pathogenesis. Therefore, in general the components of
innate immunity have predominant role in progression of
AMD.
2. Enzymes involved in metabolic processes: Hepatic Lipase
(LIPC), cholesteryl ester transfer protein (CEPT) and
Apolipoprotein E (APOE) are involved in different stages of
lipid metabolism.
3. Angiogenic factors: VEGF has been reported as the strongest
angiogenic factor. Several angiogenic factors which have been
FIGURE 1 | Illustrative representation of interaction of Genetic and environment factors.
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reported till now are either associated with AMD or are
reported to be associated with degenerative and inflammatory
diseases. e.g., VEGF, COL genes, TGFBR1, immediate early
response (IER3) etc.
4. Proteases: Several proteases have been implicated in AMD
pathophysiology including degradation of extracellular
matrix. For example, Tissue inhibitor metalloprotenases 3
(TIPM3), IER3 and numerous multifunctional proteins which
have several cellular functions like ADMS2, HTRA1 etc. play a
non redundant role in pathologies of AMD.
5. Proteins in apoptosis and cellular regulation: e.g., TNFRSF10A
and regulatory cellular enzymes likeDICER.
AMD literature is replete with both confirmatory and conflict-
ing reports of several genes and their polymorphisms which have
been found to be associated with AMD.
PROTEINS INVOLVES IN METABOLIC PROCESSES
Metabolic processes constitute the normal biochemical path-
ways in the cell which are involved in transportation and
biosynthesis of biomolecules including several regulatory pro-
cesses of the cells. AMD can be regarded as a disease caused
by disruption or abnormal metabolic processes especially lipid
metabolism. The metabolic processes which are associated with
lipid metabolism are one of the major factors in AMD pathogene-
sis. Several enzymes which participate in lipid and lipid associated
metabolism have been found to be associated with initiation
and progression of AMD pathology. Several population based
genetic and animal based studies have revealed the role of proteins
involved in lipid metabolism and their associated receptors in
AMD. Important enzymes which participate in lipid metabolism,
including human hepatic lipase gene (LIPC), lipoprotein lipase
gene (LPL), cholesterol ester transferase gene (CEPT) and ABC
binding cassettes A1 (ABCA1) gene have been found to be associ-
ated with AMD pathology. Lipoprotein lipase acts when systemic
cholesterol levels fall along with the function of ABCA1 leading
to formation of APOE, APOA1 and HDL. When cholesterol
levels rise, the action of CEPT comes into play which removes
the cholesterol ester (CE) from HDL and convert into LDL by
enzymatic process. LIPC and LPL both have dual functions i.e., as
triglyceride hydrolase as well as in receptor mediated endocytosis
of cholesterol at different stages of metabolism.
Recent studies have demonstrated composition and sub-
structures of drusen comprising of 3.2% dry weight of long
fatty acid esterified and non-esterified cholesterol and about 30
different types of proteins, including apolipoproteins (apo E and
apo B) (Burns and Feeney-Burns, 1980; Pauleikhoff et al., 1992;
Crabb et al., 2002; Li et al., 2005). Lipid metabolizing enzyme
human Lipase C (LIPC) is expressed in hepatic cells and adrenal
gland whose principal function is to convert intermediate-density
lipoprotein (IDL) to low-density lipoprotein (LDL) which have
been widely investigated in AMD. The lipids and lipoprotein con-
tents of drusen between Bruch’s membrane and RPE are basically
distinct from the plasma contents and are comprised of free and
esterified cholesterol, phosphotidylcholine (PC), apolipoproteins
B-100, A-I and ApoE (Curcio et al., 2001; Wang et al., 2010). Sev-
eral genetic studies have investigated the association of LIPC with
AMD pathogenesis. Recently, Neale et al. (2010) implicated the
association between AMD and a variant in the hepatic lipase gene
(LIPC) (rs493258). They found LIPC association was strongest
for a functional promoter variant, rs10468017, that influences
LIPC expression and serum HDL levels with a protective effect
of the minor T allele (HDL increasing) for advanced wet and dry
AMD.
ApoE, another protein, also involved in lipid transportation
and metabolism has also been extensively investigated in AMD
pathology. ApoE is a polymorphic protein which plays multi-
ple roles in lipid homeostasis in central nervous system and
metabolism of plasma lipid (Mahley, 1988). APOE gene has three
different variants called APOE2, APOE3 and APOE4 which are
due to the variation in two SNPs in the APOE gene, rs429358
and rs7412.Immunoreactivity of APOE in the eye has been
restricted to Bruch’s Membrane, Müller cells, RPE, drusen and
basal deposits (Klaver et al., 1998; Anderson et al., 2001; Malek
et al., 2003). mRNAs for APOE are synthesized by the RPE and by
Muller cells in the neural retina (Anderson et al., 2001). Polymor-
phism in APOE gene is a risk factor for various neurodegenerative
diseases, and the protein has been shown in the lesions of these
disorders. APOE gene is also known to play a major role in AMD
pathology. Some association studies have reported that APOE4
variant provides some protection from developing AMD. APOE2
variant is more common in individuals with AMD and may play
a role in its progression (Klaver et al., 1998; Souied et al., 1998;
Schmidt et al., 2002; Baird et al., 2004). These results are in vari-
ance to the animal studies in whichAMD severity has been found
to be associated with ApoE4 expressing aged mice which were
subjected to high fat cholesterol. Even the major complex diseases
such as atherosclerosis, Alzheimer’s disease, and stroke, are char-
acterized by strong association betweenAPOE4allele and disease
(Kalaria, 1997; Weller and Nicoll, 2003; Enzinger et al., 2004).
Several ApoE knockout mice studies have indicated the role
of ApoE affecting systemic cholesterol levels (Plump et al., 1992;
Zhang et al., 1992). Dithmar et al. have shown ultrastructural
changes of the Bruch’s membrane in ApoE deficient mice. They
have found elevated fraction of membrane bound electron-lucent
particle accumulation between two membranes in ApoE −/−
mice as compared to control mice (Dithmar et al., 2000). Lately,
it has been found that AMD pathology, like sub-retinal drusen
deposition, drusenoid, thickening of BM, atrophy, hypo and
hyper-pigmentation of RPE are dependent on ApoE isoforms.
AMD severity has been found to be associated with ApoE4
over expressing senescent mice which were subjected to high
fat cholesterol (Nguyen-Legros and Hicks, 2000). Moreover, cell-
membrane remodeling is an essential mechanism for mainte-
nance of retina and its normal functioning (Klaver et al., 1998),
which may be regulated by APOE. Protective function of PAOE4
are believed to arise from its inability to form dimers as com-
pared to APOE2 and APOE3 variants which may permit easier
transportation of lipids through Bruch’s membrane (Souied et al.,
1998). Lipids accumulate with the advancement of age, which
may lead to the creation of hydrophobic barrier in the Bruch’s
membrane causing AMD.
On the other hand, the involvement of APOE has also been
widely explored in AD. It has been reported that severe oxidative
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changes in protein and lipid have been shown in synaptosome of
APOE knockout mice after Aβ induced insult (Lauderback et al.,
2001). However, it has also been hypothesized that APOE may
function as “pathological chaperon” in stabilizing the Aβ sheet
structure and can also alter the normal Aβ in plaque (Ji et al.,
2001). Moreover, it has also been investigated that the burden of
amyloid-β-peptide was diminished in APPV717F+/− Apoe−/− as
compared to APPV717F+/− Apoe+/− and Apoe−/− triglycerides
(TG) mice in 20 month aged mice. The burden of Aβ in the
hippocampal region was higher in Apoe+/+ transgenic mice as
compared to Apoe+/− and Apoe−/− mice. This suggests that
even though both pathologies implicated similar elements but
the final effect are quite opposite (Bales et al., 1999). Therefore,
these studies have exemplified the role of APOE in two major age
related degenerative disease, suggesting that APOE may have the
dual role in both AMD and AD.
It was also discovered that age and high fat cholesterol diet
alone were not sufficient factors to stimulate AMD pathology
apart from isoform dependent pathology. In experimental mice,
advanced features of AMD i.e., neovascularization, with the pres-
ence of VEGF in drusen, has been found to be deposited in BM
region, which was also reported earlier, implying the role of ApoE
function in both types of AMD. The components responsible
for dry AMD further stimulate genetic cascade which leads to
activation of angiogenic molecules or metalloproteases (Malek
et al., 2005). It is argued that these changes are not critical to
developmental and the disorders of developmental. Rudolf et al.
(2005) have further distinguished the role of lipid metabolism in
stimulation of angiogenic factor (VEGF) in LDL-receptor knock-
out mice. Interestingly, it has been shown that in LDL- knockout
mice, the expression of VEGF was high as compared to controls.
Another lipid metabolizing enzymes cholestryl ester transfer
protein (CEPT) is a plasma protein that plays an important role
in cholesterol metabolism by facilitating the transportation of
triglyceride and cholesteryl ester from VLDL to HDL or vice versa.
Several genetic studies have demonstrated conflicting results of
CEPT association with AMD progression. Recently, Yu et al.
(2011) reported no association between CEPT polymorphism
and AMD pathology but demonstrated that other cholesterol
metabolizing enzymes like LIPC and a cholesterol transporter
protein ABCA1 may have role in AMD pathophysiology such that
the cumulative effect gets manifest in ageing and not earlier in life.
Several cholesterol metabolic intermediates have been found
to stimulate pathological mechanisms involved in AMD like
angiogenesis, inflammation etc. 7-ketocholesterol (7-Kch), one
of the oxidized component of cholesterol metabolism, has been
found to stimulate angiogenic factors and inflammatory processes
(Ignacio and Larrayoz, 2010). Oxidation of cholesterol into 7-Kch
is carried out by both enzymatic and non-enzymatic processes.
Non-enzymatic processes are carried out by the involvement of
singlet oxygen species and free radical mechanism. The mech-
anism mediated by singlet oxygen species requires photosensi-
tizer (Thomas et al., 1987) and free radical based mechanism
carried out by the involvement of metal catalysts like Cu+2/Fe+2
(Dzeletovic et al., 1995; Brown et al., 1996). These studies have
also suggested the probable role of Fe+2 and oxidation mediated
processes in AMD pathophysiology. Currently, only free radicals
based mechanisms have been found to be occur in retina,
however, no evidence for singlet mediated cholesterol oxidation
into 7-Kch has been reported.
Most important enzymatic oxidation of cholesterol takes
place with the involvement of CYT46A1 and CYP27A1 loci of
cytochrome P450 family which forms 24-hydroxycholesteorl (24-
Hch) and 27-hydroxycolesterol (27-Hch), respectively (Björkhem
et al., 2009). The high levels of 27-Kch have been reported in
macrophages foam cells and in atherosclerotic plaque, but has not
been documented in retina (Björkhem et al., 1994; Luoma, 2008).
These population based genetic studies coupled with animal
experiments indicate a prominent role of cholesterol metabolism
in AMD pathology indicating the longitudinal and cumulative
effects that do not alter phenotype earlier in life. Recently, it
has been demonstrated that the metabolic components of lipid
metabolism influence and activate the angiogenic factors, com-
plement factors and other regulatory components by disrupting
their regulatory pathways not critical in early life.
EFFECTS OF CHOLESTEROL METABOLISM INTERMEDIATES
ON COMPLEMENT FACTORS
Data from the previous research strongly indicates that the dys-
regulation of innate innunity can induce and result in progression
of AMD. Several GWAS and rare variants analysis studies have
strongly specified the role of alternative complement pathway in
AMD (Richards et al., 2007; Anderson et al., 2010; Raychaudhuri
et al., 2011; Khandhadia et al., 2012; Tuo et al., 2012) and it
has been well established that the dysregulation of complement
pathways, especially alternative complement pathway is respon-
sible for AMD pathophysiology and aberrant regulation of these
factors may lead to progression of AMD.
Recently, several studies have demonstrated the effects of
cholesterol metabolic components which influence these inter-
mediate components like in case of atherosclerosis. It has been
already established by Hasselbacher et al. in 1980 that choles-
terol has high potential to activate the alternative comple-
ment pathways componetnts which have been demontrated by
immunoelectrophoretic reactivity of C3 and properdin factor
B (Hasselbacher and Hahn, 1980), however none of the the
complement factors was activated when liposomes, containing
sphingomyelin as a phospholipid (Alving et al., 1977), was
used. Therefore, these studies have suggested the potetial role of
cholesterol intermediates and alternative complement pathway in
influencing disease outcome. The mechanism behind cholesterol
dependent complement activation has been illustrated and found
to be associated with C5/C3 conversion into cholesterol crys-
tals which consequently induce alternative complement cascades
which may be stabilized by factor B and D. It has also been
examined that factor I (inactivator of factor C) shows affinity with
cholesterol crystals thus indicating cholesterol mediated comple-
ment pathway activation proceeds by transformation activity not
by the involvement of factor C (Vogt et al., 1985). Consistent
with these studies the generation of anaphylatoxins and C5b-9
complex has also been observed and suggested to play a role in the
inflammatory processes mediated by cholesterol and its interme-
diators, as seen in artherosclorosis, AMD and Alzheimers disease
(Seifert and Kazatchkine, 1987). The accumulation of lipofuscin,
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with several oxysterol, have been shown to have amplified CFH
activity along with increased C3b suggesting lipid intermedi-
ate based complement dysregulation. This may lead to features
reminscent of AMD pathology (Sparrow et al., 2012). Recently, it
has been further reported that the CFH interaction with oxidized
products of cholesterol can modulate the protective effect of
CFH. The protective allele of CFH in AMD rs1061170 has been
shown to exert strong affinity and inhibitory effect of CFH upon
binding with oxidized phospholipid mediated by changes in the
expression of genes responsible for neovascularization, inflam-
mation and macrophages infiltration. This study has suggested
the interaction of oxidized phospholipid could bring changes in
the protective role of CFH by modulating other genes involving
various processes associated with AMD pathology (Shawa et al.,
2012). Additionally, Sharma et al. have also shown the reduced
levels of CFH in AMD patients (Sharma et al., 2013b). Similarly
the same group, also reported altered CCL-2 levels in AMD
patients (Anand et al., 2012). Both results suggest that impaired
macrophages recruitment in AMD pathology.
Apart from interaction and effects on complement factors,
lipid metabolic intermediates have also accounted for their direct
consequences on inflammatory responses by affecting gene reg-
ulation involved in such processes. Through in vitro studies by
Shawa et al. (2012) it has been demonstrated that the interaction
of oxidized phospholipids could upregulate the expression of
CCR-2, IL-6, IL-8, CD-36 and VEGF. The increased expression of
CCR-2 suggests augmented infiltration of macrophages at the site
of accumulated oxidized phopholipids which further influence
the intergrity of RPE cells by modulating the expression levels of
proinflammatory, inflammatory and angiogenic factors through
NFkB pathway. Recently, Amaral et al. have shown in a rat model
that the administration of 7-Kch which induces the macrophage
infiltration at site of accumulation, have displayed increased
immunolocalization of CD68 (Amaral et al., 2013). This could
result in enhanced expression of proinflammatory genes along
with angiogenic factors in moncytic THP-1 cells (Erridge et al.,
2007). Additionally, several in vitro studies have also shown that
accumulated intermediates of lipid and cholesterol metabolism
can induce the endoplasmic reticulum (ER) stress (Lee et al.,
2009; Huang et al., 2012) by involvement of various NFkB path-
ways (Dugas et al., 2010; Larrayoz et al., 2010; Huang et al.,
2012).
The role of macrophages in atherosclerosis against oxys-
terols have also been extensively investigated. These studies sug-
gest that the regulation of synthesis of inflammatory factors
like TNF-α, IL-8, IL-6 etc. is mediated by MEK/ERK and AP-
1 processes (Lemaire-Ewing et al., 2005, 2009; Erridge et al.,
2007). The inhibition of these proinflammatory factors induced
by some oxysterols could be regulated via liver X receptor
(LXR) possessing the capacity to suppress their synthesis at
the time of atherosclerosis (Calkin and Tontonoz, 2010; Im
and Osborne, 2011). Collectively, these studies indicate that
macrophages mediated proinflammatory processes induced by
accumulated lipid/cholesterols intermediates play a major role in
diseases like Alzheimer’s disease, Atherosclerosis and AMD all of
which occur with ageing. Lately, an elaborate role of cholesterol
in macrophages have been illustrated by participation of lipid
metablic processes in AMD. Sene et al. have demonstrated that
impaired cholesterol transport in macrophages could influence
the macrophages polarization into particular cell type conse-
quently impacting the pathological hallmarks in AMD (Sene et al.,
2013).
Conclusively, these studies have suggetsed the importance
of lipid/cholesterol metabolites in inducing the AMD patho-
logical hallmarks by several regulatory components of innate
immunity.
These studies demontrate that lipids/cholesterol metabo-
lites have their impact on regulation of complement factors,
interaction with protective variant of CFH and its modu-
lation, macrophage infiltration, and regulation of proinflam-
matory/inflammatory genes suggesting the role of cholesterol
metabolism and its metabolites on the complement pathway.
These studies also suggest that cholesterol transport influences the
role of macrophages in progression of AMD such that these effects
do no operate early in life.
CHOLESTEROL METABOLITES AND ANGIOGENIC FACTORS
Lipids and choleserols are essential for biological functions rang-
ing from membrane trafficking to signal transduction and can
activate various important regulatory molecules which could be
associated with several pathological hallmarks of different types
of diseases. Several studies have increased our understanding of
direct relation of lipids and cholesterol intermediates in patho-
genesis of inflammatory diseases and diseases affected by lipids
deposition, at the molecular and cellular level. Neovasculariza-
tion is one of the common features which affects about 10%
of total AMD and can be influenced by several intermediates
of cholesterol metabolism. Both angiogenic factors as well as
matrix metalloproteases (MMP) can contribute in the progres-
sion of pathophysiology of choroidal neovascularization (CNV)
in AMD. VEGF expression, expression of proangiogenic fac-
tors, and activation of metalloproteases are believed to play an
important role in the formation of CNV in AMD. It is well
understood that the biologic activities of VEGF-A, proangiogenic
molecules like (TGFB, TIMP, IER etc.) and proinflammatory
cytokines can be influenced by the interaction of cells with
the extracellular matrix (ECM). Cell-ECM interaction, useful
for integrity and functionality of cell, are influenced by the
expression of these factors (VEGF, angiogenic and proangiogenic
factors). ECM protein channel-ECM communications influence
tissue remodeling events, including angiogenesis. Several angio-
genic factors have been widely studied as one of the cardial
feature of AMD pathophysiology: “neovascularization”. The neo-
vascularization being the consequence of dysregulated action
of genes involved in proangiogenesis, angiogenesis, extracellu-
lar proteins, and metalloproteases is the central thesis in wet
AMD. These effects are additive, rarely affecting development
milestones. VEGF, one of the potent angiogenic factor known,
plays an important role in new vessels formation because it is
involved in vascular development and have been strongly impli-
cated and reported in the pathogenesis of AMD (Carneiro et al.,
2012) as well as corneal neovascularization (Philipp et al., 2000).
The VEGF family mainly binds with three types of VEGFRs
which include: VEGFR1, VEGFR2, and VEGFR3, as well as to
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co-receptors [such as heparan sulphate proteoglycans and neu-
rophilin] (Hiratsuka et al., 1998). It has been investigated that
the expression of VEGF can be influenced by components of
complement pathway. When RPE cell culture were exposed with
C3a/C5a, also present in drusen, it can significantly increase
the expression of VEGF (Nozaki et al., 2006). Recently, we also
reported VEGFR2 in AMD patients which are found to be
significantly associated with disease pathology (Sharma et al.,
2012a).
Similarly, TGFBR1 also possesses the property to exert proan-
giogenic effects with its encoded protein forming a heteromeric
complex with type II TGF-beta receptors and transducing the
TGF-beta signal from the cell surface to the cytoplasm when
bound to TGF-beta. This protein is a serine/threonine protein
kinase. This gene is expressed in all tissues but more abundantly
expressed in brain and heart. This protein is involved in sev-
eral biological processes like induction of apoptosis, response to
hypoxia, epithelial to mesenchymal transition, artery morpho-
genesis, signal transduction, regulation of transcription, negative
regulation of endothelial cell differentiation, positive regulation of
cell proliferation, collagen fibril organization etc.
Apart from above mentioned angiogenic genes, IER3 has
been postulated to be responsible for regulating death recep-
tor mediated apoptosis, interaction with NF-κB pathways, and
upregulated at irradiation, ionizing radiation, viral infection and
at the time of other cellular responses. Numerous functional
data relying on cell culture based studies and knock-out mouse
models has revealed the involvement of IER3 expression in
immune functions and in the physiology of the cardiovascular
system. Arlt et al. showed that deficiency of IER3 expression in
mice results in an aberrant immune regulation and enhanced
inflammation, hypertension or impaired genomic stability (Arlt
and Schäfer, 2011). Another report has documented the genetic
network in injured retina reporting increased expression of Ier3
gene with other transcription factors such as Crem, Egr1, Fos,
Fosl1, Junb, Btg2, Atf3, and Nr4a1 etc. Together, these genes
implicate an angiogenic pathway attributed to CFH independent
mechanism, popularly accepted to be responsible for almost
half of AMD cases. None of these gene loci or their networks
have been reported to be involved in a development disor-
der. Sasada et al. has also reported the effect of IER3 which
interferes with certain signaling pathways specifically NF-kB,
MAPK/ERK and PI3K/Akt and have found aberrant immune
function and increased inflammation, with an alteration of blood
pressure and impaired in genomic stability (Sasada et al., 2008).
Numerous patients based studies have also indicated a role of
IER3 in tumorigenesis. In pancreatic cancer patients, signifi-
cant negative correlations have been observed between the IER3
expression and serosal or arterial invasion of tumors. Thus, a
positive IER3 expression in tumor tissues may be associated
with a better prognosis in pancreatic cancer (Sasada et al.,
2008).
Several studies have been carried out to examine the effect
of deposited oxidized sterols and 7-Kch on the expression pat-
tern of these angiogenic proteins like VEGF. The effect of oxi-
dized cholesterol and 7-Kch has been widely investigated in
both animal as well as in vitro studies being responsible for
inflammtory processes at accumulation site. Moreover, recent
studies have validated the reports that phospholipidosis could
increase several times in retina when exposed with these choles-
terol intermediates (Miguet-Alfonsi et al., 2002; Vejux et al.,
2008). Even though the activation of complement factor can also
alter the expression of metalloproteases 2/9 as well as their activity
along with imbalance in VEGF to PEDF ratio, these results suggest
the effect of activated complement which could further induce
the proangiogenic environment for neovascularization in AMD
(Bandyopadhyay and Rohrer, 2012). Therefore, the activated
complement components with oxidized sterols and 7-Kch can
directly influence the expression of angiogenic and proangiogenic
molecules.
Knockout mice for ApoE and the mice feeding high fat diet
have shown several AMD like characteristics features. Increased
implicit time and reduced oscillation potential amplitude were
observed in these mice. Moreover, the scanning electron micro-
scopic examination has also revealed that thickening of Bruch’s
membrane and disorganized elastic lamina which results in stim-
ulation of choroidal angiogenesis beneath the Bruch’s membrane.
Therefore, the such studies suggest the role of ApoE and choles-
terol which may provoke the nearby environment of RPE, Bruch’s
membrane and molecules involved in adhesion of RPE and lam-
ina by stimulating the angiogenic factors and matrix proteases
(Ong et al., 2001).
Recently, the mechanistic view of activation of proangio-
genic/angiogenic factors by oxidized sterols, 7-Kch or by impaired
cholesterol transfer has been demonstrated by several inves-
tigators (Figure 2). Sene et al. (2013) had discovered the
existence of impaired cholesterol transport in macrophages
affecting ATP binding cassette A1 (ABCA1) transporter con-
verting the naive macrophages into senescent macrophages.
The effect of cholesterol accumulation inside macrophages
has been found to be abnormal polarization of macrophages
into two populations. The macrophage M1 only secretes
proinflammatory and inflammatory components but polar-
ization of M1 to M2 could pilot the secretion of angio-
genic factor like VEGF, IL-8 etc. Therefore, these studies
together signify the importance of cholesterol metabolism in
AMD which is altered in neovascularization of choroid blood
vessels.
The immediate effects of these deposited oxidized choles-
terol components have also been examined in higher verte-
brate i.e., monkey etc. The cholesterol intermediates 7-Kch have
also shown the capacity to induce VEGF in monkeys. Moreira
et al. have attempted to figure out the localization of 7-Kch
in retina and examine the impending consequences by deposi-
tion of these oxidized cholesterol products in higher primates.
The immunolocalization studies define the location of 7-Kch
which was found to be deposited in between of choriocapil-
laries and Bruch’s membrane besides the surface of vascular
endothelial cells. This was found to be 4–5 times higher when
compared to control monkey retina. Further, in vitro stud-
ies have demonstrated the induction of VEGF in ARPE-19
cells is 8–10 folds higher in 7-Kch induced retina as com-
pared to those without induced cells. Moreover, they also found
that the expression of VEGF was decreased when inhibitor
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FIGURE 2 | Illustrative mechanistic flow chart functions of various
signaling pathways leads to altered expression of
angiogenic/proangiogenic factors influence by impaired transport
and deposition of cholesterol or oxidized cholesterols due to
hampered action of ABCA1 transporter. The deposited oxidized
cholesterols components also have shown higher affinity with protective
allele of CFH i.e., rs1061170 which can also changes the expression of
angiogenic molecules.
for LXR receptor was exposed with anatagonist, however, no
change in expression was noticed when activity of NFkB was
inhibited, except IL-8. The study implies the role of 7-Kch in
CNV induced by VEGF may be partially regulated by LXR
receptor but independent on HIF-1 α and NFkB (Moreira et al.,
2009).
APOPTOSIS MEDIATED BY OXIDIZED CHOLESTEROL AND
7-Kch
The 7-Kch exerts toxic effects by inflammation (Vejux et al.,
2008; Larrayoz et al., 2010) and subsequently induce apopto-
sis of RPE cells mediated by mitochondrial apoptotic path-
way (Miguet-Alfonsi et al., 2002; Ignacio and Larrayoz, 2010).
Accumulated oxidized sterols, 7-Kch and impaired choles-
terol transport leads to increase the level of Ca+2 inside
cell mediated by Trp channel. This increased Ca+2 levels
can activate the two types of apoptotic mechanisms: (i)
dephosphorylation of “BH3 only protein Bad” which leads
to mitochndrial apoptotic pathway; and (ii) activation of
“pro-apoptotic BH3 only protein Bim” ultimately inducing
apoptosis by inhibiting the activity of Bcl-2 family members
proteins along with microtubultes destabilization (Figure 3).
Recently, we have reported the reduced DcR1 (TNF-related
apoptosis-inducing-ligand receptor-3) levels in AMD patients
(Anand et al., 2014) where the angiogenic factors like CCR-3,
VEGFR2, and eotaxin-2 (Sharma et al., 2012a,b, 2013a) were
found to be increased in serum of these patients. These reults
suggested the role of angiogenic factors with the involvement of
apoptotic molecules may contribute to the disease pathology in
these patients.
CONCLUSION
Several age related disorders like AD, Parkinson’s disease
(PD), atherosclerosis and AMD can be distinguished by sev-
eral pathological hallmarks that appear at the time of age-
ing. Collectively, these studies suggest the imperative role
of metabolic processes and various oxidized products which
exert their additive effect on both complement and proan-
giogenic/angiogenic molecules with time. Several such reports
indicate that altered cholesterol metabolism leads to patholog-
ical changes which results in accumulation of sterols, APOE,
cholesterol oxidase and oxidized cholesterols in these dis-
eases of ageing (Kannel et al., 1971; Martins et al., 2006;
Moreira et al., 2009). The altered levels of LDL, HDL,
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FIGURE 3 | Schematic of apoptosis process Induced with accumulated oxidized cholesterols (i.e., 7-Kch) by activating several apoptotic pathways.
ApoAI, ApoB and TG in AMD pathology is thus not a
coincidence as these are rarely reported in developmental
disorders (Nowak et al., 2005; Reynolds et al., 2010; Davari et al.,
2013).
In this context, the generality of need to compare the critical
mechanisms distinguishing an ageing disorder such as AMD
from mechanisms akin to developmental disorders can provide
insight for future interventions. Understanding the molecular
mechanisms that prevent AMD from being a developmental
disorder may therefore lead to effective therapies in future. For
this, longitudinal comparative studies between developmental
and degenerative disorders are warranted.
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